| Article Access Statistics|
| Viewed||5927 |
| Printed||116 |
| Emailed||1 |
| PDF Downloaded||175 |
| Comments ||[Add] |
Click on image for details.
|Year : 2005 | Volume
| Issue : 4 | Page : 273-274
Crohn's disease associated enteropathic arthritis: An often-overlooked entity
A Wanchu1, RK Dhiman2
1 Departments of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India
2 Departments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India
R K Dhiman
Departments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Wanchu A, Dhiman R K. Crohn's disease associated enteropathic arthritis: An often-overlooked entity. J Postgrad Med 2005;51:273-4
This is the first study of its kind from India where the prevalence of Crohn's disease (CD) among individuals presenting with enteropathic arthropathy. The authors found that 14 of the 29 patients studied had histologically confirmed CD. Among individuals with CD there was a significantly higher frequency of individuals with weight loss, fever, perianal fistula, abdominal pain, dysentery, and uveitis. Among these factors, logistic regression analysis showed loss of weight as only independent predictor of CD.
While there are obvious limitations in a retrospective analysis, this study brings forth several interesting issues. First, it would serve to create a greater awareness among those caring for these individuals regarding the need to perform colonoscopy among those who present with manifestations of enteropathic arthritis. Second, treatment of these individuals has involved the use of a combination of methotrexate and sulphasalazine as opposed to the latter alone for peripheral arthritis associated with other seronegative spondyloarthopathies. For the most part the dictum has been to treat peripheral arthritis in males with sulphasalazine alone if differentiation into specific syndromes is not possible. The combination is required only if one agent alone does not produce in satisfactory response. Thirdly, differentiation from tuberculosis (TB) is essential not only since antitubercular therapy is indicated there, but also since anti-tumor necrosis factor, which has been used for CD, increases the probability of reactivation of TB.
One issue that merits special consideration is the use of advanced statistical techniques in studies where the readers might be interested in applying the results to individual patients. Thus, while the patients who were first seen upto August 1998 and followed for more than 6 years, the mean duration of follow up of patients with CD was 5.54 years and those without CD was 3.27 years when none of the patients dropped out in this period.
The paper should encourage other workers in this area to consider CD as a probable diagnosis among those who present with enteropathic arthropathy.
| :: References|| |
|1.||Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum Dis Clin North Am 2003;29:513-30. [PUBMED] |
|2.||Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med 2005;118:592-603. [PUBMED] [FULLTEXT]|